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Abstract
Background: Flat epithelial atypia (FEA) of the breast is characterised by a few layers of mildly atypical luminal
epithelial cells. Genetic changes found in ductal carcinoma in situ (DCIS) and invasive ductal breast cancer (IDC)
are also found in FEA, albeit at a lower concentration. So far, miRNA expression changes associated with invasive
breast cancer, like miR-21, have not been studied in FEA.
Methods: We performed miRNA in-situ hybridization (ISH) on 15 cases with simultaneous presence of normal
breast tissue, FEA and/or DCIS and 17 additional cases with IDC. Expression of the miR-21 targets PDCD4, TM1
and PTEN was investigated by immunohistochemistry.
Results: Two out of fifteen cases showed positive staining for miR-21 in normal breast ductal epithelium, seven
out of fifteen cases were positive in the FEA component and nine out of twelve cases were positive in the DCIS
component. A positive staining of miR-21 was observed in 15 of 17 IDC cases. In 12 cases all three components
were present in one tissue block and an increase of miR-21 from normal breast to FEA and to DCIS was observed
in five cases. In three cases the FEA component was negative, whereas the DCIS component was positive for miR-
21. In three other cases, normal, FEA and DCIS components were negative for miR-21 and in the last case all
three components were positive. Overall we observed a gradual increase in percentage of miR-21 positive cases
from normal, to FEA, DCIS and IDC. Immunohistochemical staining for PTEN revealed no obvious changes in
staining intensities in normal, FEA, DCIS and IDC. Cytoplasmic staining of PDCD4 increased from normal to IDC,
whereas, the nuclear staining decreased. TM1 staining decreased from positive in normal breast to negative in
most DCIS and IDC cases. In FEA, the staining pattern for TM1 was similar to normal breast tissue.
Conclusion: Upregulation of miR-21 from normal ductal epithelial cells of the breast to FEA, DCIS and IDC
parallels morphologically defined carcinogenesis. No clear relation was observed between the staining pattern of
miR-21 and its previously reported target genes.
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Background
Flat epithelial atypia (FEA) was first proposed as an entity
in 2003 in the World Health Organization classification
of tumours of the breast [1]. It is defined as an intraductal
neoplasm, characterized by the replacement of original
epithelial cells by a single or 3–5 thick layer of mildly
atypical cells with loss of polarization. However recent
insights show that FEA actually consists of dilated lobules,
rather than dilated ducts [2]. With the wide application of
mammography screening in women, FEA is more fre-
quently detected since calcification is relatively common
in FEA. Although FEA is intensively studied there is still
disagreement on how to deal with it in clinical patient
care, since only few patients in whom only FEA was diag-
nosed developed subsequent breast cancer [3,4]. Patients
with ductal carcinoma in situ (DCIS), a known premalig-
nant lesion that needs to be treated, show concurrent FEA
in about 30% of patients. For that reason it is interesting
to study whether FEA has to be regarded as a true prema-
lignant lesion or only as an indolent precursor lesion,
with or without relationship with DCIS.
Loss of heterozygosity on 3p, 9q, 10q, 11q, 17p, 17q, and
recurrent gains on 15q, 16p and 19 have been observed in
approximately 10 to 50% of FEA [5-7]. These genomic
aberrations are also found in DCIS and invasive ductal
carcinoma (IDC) and suggest that FEA might indeed be
considered as a premalignant lesion, which can develop
into DCIS or IDC. Recent insights in oncogenesis have
revealed that micro-RNAs (miRNAs) can play crucial roles
in malignant transformation acting as onco-miRNAs or
tumour suppressor miRNAs [8].
MiRNAs are small noncoding single stranded RNAs of
about 21–23 nucleotides, which negatively modulate pro-
tein expression by targeting mRNA transcripts and trigger-
ing either translation repression or RNA degradation [9-
12]. MiR-21 (miR-21) is one of the most studied miRNAs
in cancer and is highly upregulated in breast cancer as
compared with normal tissue [13,14]. Mir-21 levels were
higher in grade 2 and 3 as compared to grade 1 IDC [14].
So far, only a few miR-21 target genes have been identified
in several cancer types including breast cancer. Zhu et al.
showed that miR-21 targets the tumor suppressor gene,
Tropomyosin 1 (TM1) [15]. Frankel et al[16] demon-
strated that inhibition of Programmed Cell Death 4
(PDCD4) in MCF-7 cells significantly alleviated the anti-
proliferative effect of miR-21 inhibition. Chan et al.
showed that miR-21 acts as an anti-apoptotic factor in
human glioblastoma cells [17]. In hepatocellular cancer
miR-21 regulates the expression of the tumor suppressor
gene phosphatase and tensin homolog (PTEN) [18].
Although several studies focus on the expression of miR-
21 in breast cancer, there are no studies on the expression
of miR-21 in FEA. We performed miRNA ISH, which
allows accurate and direct detection of miR-21 in normal,
FEA, DCIS and IDC breast tissue. The expression of the
experimentally confirmed target genes, PTEN, PDCD4
and TM1 were studied in normal, FEA, DCIS and IDC.
Methods
Specimen collection and processing
Twenty-five patients with simultaneous FEA and DCIS
were identified in a series of 270 cases of DCIS diagnosed
from January, 2004 to December, 2006 in the Department
of Breast Cancer Pathology and Research Laboratory, Can-
cer Hospital of Tianjin Medical University, Tianjin, China.
Twenty-one IDC cases were selected from University Med-
ical Center Groningen (UMCG), Groningen, The Nether-
lands. All of the specimens were fixed by 10% formalin
and embedded in paraffin. Fifteen patients with simulta-
neously FEA and/or DCIS were selected for miR-21 RNA-
ISH based on a strong and homogeneous positive staining
for β-actin using RNA-ISH, indicating a good quality of
RNA in the tissue blocks. Seventeen of the 21 IDC (includ-
ing three stage 1, nine stage 2 and nine stage 3 cases) con-
tained good quality RNA and also showed a homogenous
staining pattern over the tissue sections as determined by
performing β-actin RNA-ISH. This selection criterion is
important for this study since we want to compare the
staining intensities in different tissue components within
the same tissue block. FEA was morphologically defined
as described in the Background. Additionally its existence
was immunohistochemically confirmed using a panel of
cytokeratins (CK8/18, CK5/6 and CK14). Only a mono-
morphic and monotypic CK8/18 positive intraductal cell
proliferation was regarded as FEA, whereas mixtures of
CK8/18 positive cells together with CK5/6 or CK14 posi-
tive cells were regarded as (benign) ductal hyperplasia
[1,2,19,19]. DCIS and invasive carcinoma were morpho-
logically defined using standard criteria [1]. All study pro-
tocols were approved by the local medical ethical
committee of the University Medical Centre Groningen.
For the tissue specimens from China, protocols were
approved by the Tianjin Medical University Administra-
tive Panel on Human Subjects in Medical Research and
the institutional Review Boards of Tjanjin Cancer
Research institution.
β-actin RNA-ISH
β-actin RNA-ISH was performed on routinely fixed paraf-
fin-embedded tissue sections by use of standard labora-
tory protocols. In short, paraffin tissue sections were
deparaffinized and air-dried for 10 min. Slides were
treated with proteinase K (Roche, 15 μg/ml) at 37°C for 1
hr. After being washed with PBS, slides were incubatedBMC Cancer 2009, 9:163 http://www.biomedcentral.com/1471-2407/9/163
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with 1 ng/μl anti-sense β-actin DIG-labeled probe (Roche,
Mannheim, Germany) in a hybridization solution con-
sisting of 5× Denhardt's solution, 2× SSC, 10% dextran
sulphate, 30% formamide, 1 mg/ml t-RNA, and 2 mg/ml
salmon sperm DNA, overnight at 55°C. After being
washed, slides were treated with 10 mg/ml RNase (Sigma-
Aldrich, Steinheim, Germany) at 37°C for 30 min,
washed and incubated with anti-DIG-labeled alkaline
phosphatase Fab fragments (Roche) for 1 hr in 0.1 M
maleic acid buffer containing 0.15 M NaCl, 2% blocking
buffer, and 1% Triton X-100. Staining reaction was per-
formed overnight with 4-Nitro blue tetrazolium chloride
(NBT) (Roche) and X-phosphate/5-Bromo-4-chloro-
3indolyl-phosphate (BCIP) (Roche) in 50 mM Tris-HCl,
150 mM NaCl, 50 mM MgCl2 pH = 9.7 buffer. In all
experiments a negative control, i.e. staining without β-
actin probe, was included.
miR-21 ISH
MicroRNA-ISH was performed on routinely fixed paraf-
fin-embedded tissue sections. Paraffin tissue sections were
deparaffinized with xylene, rehydrated with ethanol dilu-
tion series and treated with 15 μg/ml proteinase K
(Roche) at 37°C for 15 min. After a washing step with
0.2% Glycine in PBS, slides were fixed with 4% formalde-
hyde and washed with phosphate buffered saline (PBS),
and 2 × SSC. After drying, slides were incubated with
hybridization buffer consisting of 50% formamide, 0.25
mg/ml salmon sperm DNA, 1 mg/ml t-RNA, 0.01 M
Dithiothreitol (DTT) (Roche), 10× Denhardt's solution,
10% dextran sulphate, 4× SSC at 37°C for 2 hr. Then
slides were hybridized with 20 nM DIG-labeled miR-21
probe (Exiqon, Copenhagen, Denmark) diluted in
hybridization buffer at 51°C overnight. After washing,
slides were treated with blocking buffer (2% sheep serum,
0.1% Tween in PBS) at 37°C for 30 min. Slides were incu-
bated with anti-DIG-AP Fab fragments in blocking buffer
at 37°C for 1 hr and washed with 0.1% Tween in PBS and
AP buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM
MgCl2, 0.05% Tween 20, pH = 9.5), miR-21 was visual-
ized in a staining reaction with NBT/BCIP solution (4.5 μl
NBT, 3.5 μl BCIP, 1 μl levamisol in 1 ml AP buffer). The
last step was refreshed for 3 times over a period of 1 – 3
days until the staining was visible. In all experiments a
negative control, i.e. staining without miR-21 probe, was
included.
The slides were scored independently by two observers
and positive cases were defined when more than 10% of
the cells of interest showed a cytoplasmic staining. Dis-
crimination of weak and strong positive staining was
based on the intensity observed in different components
within the same area of the tissue section to exclude vari-
ation in staining intensity caused by differences during the
fixation procedure. In general, the signals for β-actin were
more pronounced than the signals for miR-21, supporting
our pre-selection criteria. However, in some cases miR-21
staining appeared to be more pronounced than the β-
actin staining.
IHC staining of PTEN, PDCD4 and TM1
Paraffin-embedded sections (3 μm) were deparaffinized,
rehydrated and stained using routine laboratory proto-
cols. Antigen retrieval and antibody dilutions are summa-
rized in table 1. Endogenous peroxidase was blocked with
0.3% hydrogen peroxide in phosphate buffered saline
(PBS) for 30 minutes and endogenous biotin was blocked
using a Blocking Kit (Vector Laboratories, Burlingame,
USA). The sections were incubated for 1 hour at room
temperature with antibodies diluted in 1% BSA in PBS.
The sections were subsequently incubated with secondary
and tertiary antibodies (all from DAKO) for 30 minutes.
The staining was visualized with 3,3'-diaminobenzidine
as chromogen for 10 minutes and the slides were counter-
stained with hematoxylin. Normal breast tissue was used
as a positive control for PTEN and TM1 and normal colon
tissue for PDCD4 staining. The staining patterns for all
three antibodies were compared to previously reported
staining patterns in these tissues to assess the specificity of
the staining [20-22]. For PTEN we used the same antibody
as used previously for prostate cancer [23]. For PDCD4
and TM1 specificity of the antibodies was shown previ-
ously by Western blot [24,25]. For PDCD4 normal
colonic epithelium served as positive and intestinal type
colon carcinoma served as negative control tissue (addi-
tional file 1). For TM1 colon served also as control tissue,
with the muscularis mucosa and the smooth muscle layer
around capillaries as positive and the colonic epithelium
as negative controls (additional file 1). Negative controls
Table 1: Details of immunohistochemistry procedure
Antibody clone (source) dilution Antigen retrieval
PTEN 6H2.1 (Cascade BioScience) 1:100 Microwave (10 mM sodium citrate pH = 6.0)
PDCD4 ab51495 (Abcam) 1:100 Microwave (10 mM sodium citrate buffer pH = 6.0)
TM1 (alpha) ab55915 (Abcam) 1:200 Protease 0.1%, 30 minBMC Cancer 2009, 9:163 http://www.biomedcentral.com/1471-2407/9/163
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were obtained by omission of the primary antibodies
from the staining procedure.
The staining was scored independently by two observes
and classified as: (-) negative staining; (+) weak positive
staining of 10% or more of the cell type of interest; (++)
moderate positive staining in 10% or more of the cell type
of interest; (+++) strong positive staining of 10% or more
of the cells of interest. PTEN demonstrated a nuclear stain-
ing, TM1 a cytoplasmic staining and PDCD4 showed both
cytoplasmic and nuclear staining, which was scored inde-
pendently.
Statistical analysis
Statistical analysis for comparison between normal breast
tissue, FEA, DCIS and IDC for positive rates of miR-21 was
performed using 1-sided Fisher exact test or Chi-square
test. P values less than 0.05 were considered significant.
Results
β-actin miRNA-ISH
Fifteen out of 25 tissue blocks showed a positive and
homogeneous staining pattern for β-actin RNA-ISH which
showed that the quality of the tissue specimens and the
fixation procedure resulted in sufficiently high quality
RNA for ISH throughout the whole tissue section. IDC
showed a positive staining with β-actin in 17 out of 21
cases. Ten FEA and four IDC showed no or only a very
weak and focal (restricted to the outer areas of the tissue
and not in the central regions) signal for β-actin and were
excluded due to bad quality RNA in the tissue block.
miR-21 ISH
We observed staining of miR-21 in the cytoplasm of nor-
mal breast epithelium in two out of 15 cases (13%). FEA
was present in all cases and stained positive in seven cases
(47%). For six of these seven cases, the FEA component
stained positive for miR-21, whereas the normal compo-
nent stained negative. DCIS was present in 12 cases and
stained positive in nine cases (75%) (Table 2). In 12 of the
samples, all three components were present in the tissue
section. A marked increase in staining intensity was
observed from normal breast to both FEA and DCIS in five
cases (#4, 5, 10, 11, 15) (Fig. 1). In three cases (#1, 7 and
9) staining in FEA was negative, whereas DCIS stained
positive, in three cases (#9, 12, 14) staining was negative
in all three components and in one case staining was pos-
itive in all three components (#2). IDC showed a consist-
ent strong positive signal in 15 out of 17 cases (88%) (Fig.
2). In general, the percentage of cases showing miR-21
expression was low in normal tissue (13%), and increased
in FEA (47%), DCIS (75%), and IDC (88%). Using Fisher
exact test, we found that the percentage of miR-21 positive
cases was significantly higher in IDC and DCIS compared
with normal breast tissue (P = 0.000 and P = 0.002,
respectively). Moreover, an increase of the percentage of
miR-21 positive cases was also observed in FEA (47%),
although it did not reach significant levels (P = 0.054).
PTEN, TM1 and PDCD4 staining
Normal breast tissue in all 15 cases showed a strong
nuclear PTEN protein expression. The FEA, DCIS and IDC
components also stained positive for PTEN albeit with
varying intensities (Table 3, Fig. 3).
Cytoplasmic TM1 staining was seen in luminal cells in
normal breast tissue in all cases. Similar to the normal
breast tissue, FEA also showed positive staining in all
cases. In DCIS staining was observed in ten out of 12 cases
albeit at lower intensities as compared to normal and FEA.
In IDC only seven out of 21 (33%) cases demonstrated a
positive staining for TM1. In addition, TM1 protein
expression was also seen in the cytoplasm of myoepithe-
lial cells in some cases.
Staining of PDCD4 was seen in the nuclei and cytoplasm
of luminal cells. The expression of PDCD4 was located
predominantly in nuclei in normal breast tissue (73%
positivity in nucleus versus 13% positivity in cytoplasm)
Expression of miR-21 in 5 patients presenting simultaneously  with normal breast epithelium, FEA, DCIS by RNA ISH Figure 1
Expression of miR-21 in 5 patients presenting simul-
taneously with normal breast epithelium, FEA, DCIS 
by RNA ISH. The expression of miR-21 was detected pre-
dominantly in the cytoplasm in luminal cells. An increase in 
staining intensity for miR-21 was observed from normal, to 
FEA and DCIS in these 5 patients. Staining intensity in FEA 
and DCIS was similar in 4 out of 5 cases (200×).
normal                     FEA                     DCIS
case 4
case 5
case 10
case 11
case 12BMC Cancer 2009, 9:163 http://www.biomedcentral.com/1471-2407/9/163
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and FEA (93% versus 13%), whereas in DCIS and IDC
positive cytoplasmic staining was observed in approxi-
mately half of the cases and nuclear staining was
decreased (Table 3, Fig 3).
Direct comparison of miR-21 and target gene staining 
patterns
Based on the percentage of positive cases, an inversed
trend can be observed for TM1 and miR-21, whereas, this
is less evident for both PTEN and PDCD4 with miR-21. To
further explore a possible inversed relation between the
miR-21 staining pattern and the staining patterns, we also
performed a case by case analysis. In IDC, TM1 staining is
usually negative and miR-21 positive, whereas in normal
tissue TM1 is usually positive and miR-21 negative. In FEA
and DCIS there is a trend that the strongest TM1 signals
were observed in the cases that lack miR-21 (additional
file 2). For PTEN positive staining was observed in all four
components (normal, FEA, DCIS and IDC), whereas a
clear increase of miR-21 was observed for the percentage
of positive cases from normal to FEA, DCIS and IDC
(Additional file 3). For PDCD4 combination of the signal
intensities for the nuclear and cytoplasmic staining with
the miR-21 staining also showed no clear trend. However,
the nuclear PDCD4 staining pattern does show an inverse
relation to the miR-21 staining pattern for normal and
IDC. For FEA and DCIS such a relation was not obvious
(Additional file 4).
Discussion
FEA is detected with increasing frequency, due to breast
cancer screening programs. Although several studies indi-
cate that FEA might be regarded as a premalignant lesion
whether or not via progression to DCIS, clinical follow-up
data did not unequivocally support this conclusion [3,4].
The present study confirms lack of miR-21 expression in
the vast majority of the normal breast tissue samples and
positivity in most IDC cases as previously reported
[13,14]. FEA and DCIS express miR-21in 47 and 75% of
the cases respectively.
Expression of miR-21 in IDC by RNA ISH Figure 2
Expression of miR-21 in IDC by RNA ISH. A represent-
ative example of IDC showing strong cytoplasmic staining in 
the vast majority of the tumor cells.(200×).
miR-21 ISH on IDC
Table 2: Expression of miR-21 in normal, FEA and DCIS 
detected by RNA-ISH
Patient nr. Normal breast FEA DCIS
1- - ±
2+ + +
3- + n a
4- + +
5- + +
6- - n a
7- - +
8+ -+
9- --
10 - ± +
11 - + +
12 - - -
13 - - na
14 - - -
15 - + +
Total 2/15 (13.33%) 7/15(46.67%) 9/12 (75%)
na, DCIS component not present in tissue block
Staining of three predicted miR-21 target genes in normal,  FEA, DCIS and IDC tissue Figure 3
Staining of three predicted miR-21 target genes in 
normal, FEA, DCIS and IDC tissue. PTEN showed 
nuclear staining and was expressed strongly in normal, FEA, 
DCIS and IDC. TM1 expression in normal, FEA, DCIS and 
IDC showed cytoplasmic staining and there was a decrease 
from normal to FEA, DCIS and IDC. PDCD4 was expressed 
mainly in nuclei in normal breast while the staining pattern 
gradually shifted from nuclear to cytoplasmic in FEA, DCIS 
and IDC (400× magnification for all).
normal                       FEA      DCIS                IDC
PTEN
PDCD4
TM1BMC Cancer 2009, 9:163 http://www.biomedcentral.com/1471-2407/9/163
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Recent studies showed that at least some miRNAs act as
oncogenes by playing a role in regulating proliferation
and apoptosis. MiR-21 is consistently upregulated in inva-
sive breast cancer, with a marked increase in grade 2/3
IDC as compared to grade 1 IDC cases [14]. In a single
study, RNA-ISH using fluorescently labeled probes has
been applied on breast cancer, demonstrating that miR-21
expression is frequently increased in IDC as compared
with normal breast tissue [26]. In our study, a progressive
increase of the percentage of positive cases of miR-21 was
observed from normal (13%) to FEA (47%), DCIS (75%)
and to IDC (88%). One exceptional case (#8) with posi-
tive staining in normal and DCIS, but not in the FEA com-
ponent was observed. Based on the increase of number of
positive cases from normal, to FEA, DCIS and IDC, it is
tempting to speculate that increased miR-21 in FEA might
be an indication of a pre-malignant phenotype of FEA.
These findings are in line with previous studies that
showed several genomic aberrations in a low percentage
of FEA [5-7].
Thus far, two direct miR-21 target genes have been exper-
imentally verified in breast cancer, i.e. TM1 [15] and
PDCD4 [16,27,28]. A third potential miR-21 target gene,
PTEN, was identified in hepatic cellular cancer and has
not been tested in breast cancer, so far [18]. Direct effects
of miR-21 function in breast cancer was obtained in two
more recent studies by inhibiting miR-21, which resulted
in reduced invasion and lung metastasis in MDA-MB-231
and suppressed cell growth of MCF-7 cells both in vitro
and in a xenograft mouse model [27,28].
PTEN is a tumor suppressor gene, associated with negative
regulation in the phosphoinositide-3-kinase (PI3 kinase)
pathway [29]. Meng et al. showed that the expression of
PTEN decreased in normal human hepatocytes after
induction of miR-21. Moreover, using a luciferase reporter
assay they demonstrated that PTEN is directly targeted by
miR-21 [18]. In our study PTEN expression levels were
+++ in all normal components, and ++ or +++ in the vast
majority of FEA, DCIS and IDC compartments. The slight
differences in staining intensities for PTEN in these com-
ponents together with the strong increase observed for
miR-21 from normal to IDC does not support a promi-
nent role for miR-21 induced repression of PTEN in breast
cancer. Moreover, matched analysis of miR-21 and PTEN
per component and per case, also failed to show an
inverse correlation. Previous studies have shown loss of
PTEN protein expression in IDC [20,30] and in one study
also in DCIS, albeit at a lower percentage of the cases as
compared to IDC [31]. In our series no loss of PTEN was
observed probably due to our relative small series.
PDCD4 was identified as a novel tumor suppressor gene
and it was found to be downregulated in several types of
human cancer. Frankel et al[16] demonstrated that miR-
21 targeted PDCD4 in a luciferase based reporter assay.
Moreover, they also demonstrated that downregulation of
PDCD4 in MCF-7 cells significantly alleviated the anti-
proliferative effect of miR-21 inhibition, which suggests
an essential role for PDCD4 as a mediator of the biologi-
cal effects of miR-21 in breast cancer cells. In breast cancer
a decreased expression of PDCD4 was observed in com-
parison to normal breast tissue. Expression of PDCD4 was
mainly localized in nuclei in DCIS while it was predomi-
nantly expressed in cytoplasm in normal breast tissue
[32]. In contrast, we found that the PDCD4 expression
shifted from nuclei to cytoplasm with the progression of
breast tissue from normal to IDC, whereas nuclear expres-
sion of PDCD4 decreased from normal breast to FEA,
DCIS and IDC. In colorectal cancer a shift from nuclear to
cytoplasmic staining was observed from normal tissue, to
colonic adenoma, and colorectal cancer [22] consistent
with our findings. So far, the literature concerning the
location of PDCD4 is still contradictory and there are no
clear data demonstrating the specific function of either
cytoplasmic or nuclear PDCD4. Since we only observed a
shift from cytoplasm to nucleus or vice versa and not a
marked change in the total amount of protein it is
unlikely that PDCD4 is a direct target of miR-21. How-
Table 3: Expression of miR-21, PTEN, PDCD4, TM1 immunohistochemistry staining in normal, FEA, DCIS and IDC
miR-21 PTEN TM1 PDCD4
(nuclear)
PDCD4
(cytoplasmic)
Tissue type - ± + - + ++ +++ - + ++ +++ - + ++ +++ - + ++ +++
N o r m a l  b r e a s t 1 3 0 2 0 0 01 50 4 1 004 2 4 51 3 1 1 0
F E A 8 1 6 0 3 570 2 1 0 31 0 68 1 3 0 20
D C I S 3180 03 9 263 1 831 0 642 0
I D C 2 21 3001 2 9 1 45 2 0 1 91 0 1 1 12 8 0BMC Cancer 2009, 9:163 http://www.biomedcentral.com/1471-2407/9/163
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ever, we can not exclude an indirect effect of miR-21 by
regulating a protein that is involved in PDCD4 localiza-
tion.
TM1 belongs to the family of tropomyosins (TMs) and
acts as a suppressor of cellular transformation [33]. Tar-
geting of TM1 by miR-21 was shown by the downregula-
tion of TM1 expression upon induction of miR-21 and the
upregulation of TM1 expression upon treatment with
anti-miR-21 in a breast cancer cell line [15]. Our results
showed that there was an obvious decrease in the percent-
age of positive cases for TM1 with progression, i.e. the
majority of cases being positive in both normal and FEA
and a minority of cases being positive in IDC. The staining
pattern in normal and IDC shows an inversed relation to
the miR-21 staining pattern consistent with targeting of
TM1 by miR-21. For the FEA and DCIS components this
inversed relation is less obvious.
In a recent paper, Talotta et al. showed that transcription
of the primary miR-21 transcript is induced by AP-1 in
response to RAS in the RAS inducible cell line FRTL-5/ER-
RAS [34]. In this cell line model induction of miR-21 was
responsible for the downregulation of PDCD4 and PTEN.
No decrease was observed for TM1 protein levels. These
data are not consistent with our staining results showing
a consistently high expression level for PDCD4 and PTEN
in normal, FEA, DCIS and IDC. In contrast, the staining
pattern for TM1 shows an inversed staining pattern as
compared to the miR-21 pattern. Whether this model is
relevant for the situation in breast cancer development is
questionable.
Conclusion
The percentage of miR-21 positive cases gradually
increased from normal to FEA, DCIS and IDC. Our results
demonstrate that in five out of 12 cases with simultaneous
presentation of normal, FEA and DCIS, the FEA and DCIS
components share a similar miR-21 profile. This is con-
sistent with previous publications showing similar genetic
aberrations in FEA and DCIS. An inversed staining pattern
was observed for miR-21 and TM1 in the normal and IDC
components, but not in FEA and DCIS. These findings
might support targeting of TM1 by miR-21 in breast can-
cer.
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